Bharat Biotech’s Intranasal COVID-19 Vaccine Gets Emergency Use Authorisation From DCGI
New Delhi: The Drugs Controller General of India (DCGI) on Tuesday approved Bharat Biotech’s intranasal Covid-19 vaccine for emergency use authorisation, Union Health Minister Dr Mansukh Mandaviya said on Tuesday.
“Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine has been approved for primary immunization against Covid-19 in 18+ age group for restricted use in emergency situation,” tweeted Mandaviya.
Big Boost to India’s Fight Against COVID-19!
Bharat Biotech’s ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022
Earlier in August, Bharat Biotech International Limited (BBIL) said its Covid-19 intranasal vaccine (BBV154) has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials phase III. The vaccine candidate was evaluated earlier in phase I and II clinical trials with successful results.
BBV154 has been specifically formulated to allow intranasal delivery. In addition, the nasal delivery system has been designed and developed to be cost-effective in low and middle-income countries, a press release from the vaccine maker said.
BBV154 was developed in partnership with Washington University St Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy.